HC Wainwright Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock.

IVVD has been the topic of several other research reports. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research report on Monday. Finally, Morgan Stanley lowered their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $7.89.

Invivyd Price Performance

IVVD opened at $1.06 on Tuesday. The firm has a market capitalization of $126.80 million, a PE ratio of -0.54 and a beta of 0.61. The business’s 50-day moving average is $0.50 and its two-hundred day moving average is $0.82. Invivyd has a 1 year low of $0.35 and a 1 year high of $5.10.

Insider Buying and Selling

In other Invivyd news, Director Terrance Mcguire sold 119,805 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $0.42, for a total value of $50,318.10. Following the completion of the transaction, the director now owns 3,568,274 shares in the company, valued at approximately $1,498,675.08. This represents a 3.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 816,466 shares of company stock valued at $423,214 over the last 90 days. Insiders own 17.90% of the company’s stock.

Hedge Funds Weigh In On Invivyd

Several institutional investors and hedge funds have recently modified their holdings of the business. Proficio Capital Partners LLC acquired a new stake in Invivyd in the third quarter valued at approximately $27,000. Barclays PLC raised its position in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Invivyd in the second quarter valued at about $421,000. Finally, Marshall Wace LLP increased its stake in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.